EC-BIOTECH: OVERVIEW AND ANALYSIS OF THE PANEL’S INTERIM REPORT

The WTO Panel found that the EC's de facto moratorium on biotech approvals and several product-specific delays violated procedural requirements of the SPS Agreement by causing "undue delay." Additionally, safeguard measures adopted by EC Member States (including France, Germany, Italy, and Greece) were found inconsistent with the SPS Agreement because they were not based on a risk assessment. However, the Panel ruled that the general moratorium itself was a procedural decision rather than a substantive SPS measure, meaning it was not subject to the science-based risk assessment requirements of Article 5.1. The Panel also rejected the EC's argument that the Convention on Biological Diversity and the Cartagena Protocol on Biosafety should be used to interpret WTO rules, as not all parties to the dispute were parties to those treaties.

• The WTO Panel concluded that a de facto moratorium on the approval of biotech products existed in the EC between June 1999 and August 2003, driven by a 'plan or course of action' by the Commission and a 'Group of Five countries' (Denmark, Italy, France, Greece and Luxembourg) to prevent final approvals pending new rules on labeling and traceability.
• The general de facto moratorium and product-specific measures were found to be inconsistent with Article 8 and Annex C (1)(a) of the SPS Agreement because they resulted in "undue delay" in completing approval procedures, specifically citing the case of MS8/RF3 oilseed rape.
• The Panel ruled that the general moratorium and product-specific measures were procedural decisions to delay final approvals, not substantive 'SPS measures' as defined in Annex A (1). Consequently, they were not subject to the science and risk assessment requirements of Article 5.1, 5.5, 5.6, 2.2, or 2.3 of the SPS Agreement.
• National safeguard measures adopted by EC Member States (Austria, France, Germany, Greece, Italy, and Luxembourg) to restrict biotech products already approved at the EC level were found inconsistent with the SPS Agreement for failing to be based on a risk assessment as required by Article 5.1.
• The Panel determined that the safeguard measures did not qualify for the provisional protection of Article 5.7 of the SPS Agreement because the existing EC-level scientific evaluations proved that scientific evidence was "sufficient" to perform a risk assessment.
• The Panel rejected the EC's request to interpret WTO rules using the 1992 Convention on Biological Diversity (CBD) and the 2000 Cartagena Protocol on Biosafety, stating it had no obligation to do so because not all parties to the dispute were parties to these agreements.
• The Panel found that the EC did not violate Article 10.1 of the SPS Agreement regarding special and differential treatment for developing countries, ruling that the obligation to "take account of" such needs does not require a specific result or priority over other legitimate interests.
• The Panel accepted three amicus curiae briefs from university professors and NGOs (represented by FIELD and CIEL) but ultimately stated it "did not find it necessary to take the amicus curiae briefs into account" in its decision.

APA

Bernasconi-Osterwalder, N., & Oliva, M. J. (2006). EC-BIOTECH: OVERVIEW AND ANALYSIS OF THE PANEL’S INTERIM REPORT. Center for International Environmental Law. https://www.ciel.org/wp-content/uploads/2015/03/EC_Biotech_Mar06.pdf

Chicago

Bernasconi-Osterwalder, Nathalie, and María Julia Oliva. EC-BIOTECH: OVERVIEW AND ANALYSIS OF THE PANEL’S INTERIM REPORT. Center for International Environmental Law, 2006. https://www.ciel.org/wp-content/uploads/2015/03/EC_Biotech_Mar06.pdf.

Wikipedia

{{cite report |last1=Bernasconi-Osterwalder |first1=Nathalie |last2=Oliva |first2=María Julia |title=EC-BIOTECH: OVERVIEW AND ANALYSIS OF THE PANEL’S INTERIM REPORT |publisher=Center for International Environmental Law |date=March 2006 |url=https://www.ciel.org/wp-content/uploads/2015/03/EC_Biotech_Mar06.pdf |access-date=23 October 2026 |via=Climate Insights Directory}}

BibTeX

@techreport{bernasconiosterwalder2006ecbiotech, author = {Bernasconi-Osterwalder, Nathalie and Oliva, María Julia}, title = {{EC-BIOTECH: OVERVIEW AND ANALYSIS OF THE PANEL’S INTERIM REPORT}}, institution = {Center for International Environmental Law}, year = {2006}, month = mar, url = {https://www.ciel.org/wp-content/uploads/2015/03/EC_Biotech_Mar06.pdf}, urldate = {2026-10-23}, note = {Indexed by Climate Insights Directory} }